Celonic and Carbogen Amcis partner to deliver ADC development and manufacturing platform

Ablaze and Yonghe Pharma initiate development and manufacturing agreement for targeted radiopharmaceutical therapies

Yonghe as the CDMO partner will provide production process development and cGMP manufacturing services for Ablaze

Gilead Sciences appoints Stacey Ma as EVP, Pharmaceutical Development and Manufacturing

Taiyin Yang, PhD, Executive Vice President, Pharmaceutical Development and Manufacturing to Retire After 29 Years at Gilead

Shilpa Biologicals' PartnerPower promises real-time transparency in biologics development

New digital platform provides global sponsors with live visibility into R&D, process development and GMP manufacturing operations, enhancing collaboration and decision-making

Piramal Pharma Solutions achieves 200+ customer audits, 70 regulatory approvals in FY26

CDMO strengthens global quality framework through digital transformation, AI-enabled investigations, workforce development and continuous audit readiness

ARScience Biotherapeutics appoints Gustavo Mahler as CEO

Mahler brings more than 20 years of leadership experience spanning cell therapy, biopharmaceutical development, manufacturing, and global business management

We plan to invest nearly $100 million in new infrastructure, biologics and AI-driven drug discovery,: Akhil Ravi, CEO, Aurigene

Since 2022, we have grown threefold and our growth story is built on scale, scientific innovation and deep customer partnerships

Neuland to set up $20m process development facility in Hyderabad

New facility will open by October 2026 and house 500 process development specialists

Dr Reddy’s launches first-to-market generic Bosutinib in US oncology push

Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing

Maiva Pharma inaugurates advanced sterile injectables manufacturing facility in Tamil Nadu

New Shoolagiri plant strengthens Maiva’s global CDMO capabilities with advanced isolator technology, flexible production lines, and expanded capacity for complex injectable therapies